254 related articles for article (PubMed ID: 36183389)
1. Mitochondria and vascular calcification in chronic kidney disease: Lessons learned from the past to improve future therapy.
Pongsuwan K; Kusirisin P; Narongkiattikhun P; Chattipakorn SC; Chattipakorn N
J Cell Physiol; 2022 Dec; 237(12):4369-4396. PubMed ID: 36183389
[TBL] [Abstract][Full Text] [Related]
2. CKD, arterial calcification, atherosclerosis and bone health: Inter-relationships and controversies.
Reiss AB; Miyawaki N; Moon J; Kasselman LJ; Voloshyna I; D'Avino R; De Leon J
Atherosclerosis; 2018 Nov; 278():49-59. PubMed ID: 30253289
[TBL] [Abstract][Full Text] [Related]
3. Contribution of Gut Microbiota-Derived Uremic Toxins to the Cardiovascular System Mineralization.
Filipska I; Winiarska A; Knysak M; Stompór T
Toxins (Basel); 2021 Apr; 13(4):. PubMed ID: 33920096
[TBL] [Abstract][Full Text] [Related]
4. Irisin alleviates vascular calcification by inhibiting VSMC osteoblastic transformation and mitochondria dysfunction via AMPK/Drp1 signaling pathway in chronic kidney disease.
Wang PW; Pang Q; Zhou T; Song XY; Pan YJ; Jia LP; Zhang AH
Atherosclerosis; 2022 Apr; 346():36-45. PubMed ID: 35255258
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular risk in chronic kidney disease (CKD): the CKD-mineral bone disorder (CKD-MBD).
Hruska KA; Choi ET; Memon I; Davis TK; Mathew S
Pediatr Nephrol; 2010 Apr; 25(4):769-78. PubMed ID: 19898875
[TBL] [Abstract][Full Text] [Related]
6. Metformin prevents the development of severe chronic kidney disease and its associated mineral and bone disorder.
Neven E; Vervaet B; Brand K; Gottwald-Hostalek U; Opdebeeck B; De Maré A; Verhulst A; Lalau JD; Kamel S; De Broe ME; D'Haese PC
Kidney Int; 2018 Jul; 94(1):102-113. PubMed ID: 29716795
[TBL] [Abstract][Full Text] [Related]
7. Vascular calcification and renal bone disorders.
Lu KC; Wu CC; Yen JF; Liu WC
ScientificWorldJournal; 2014; 2014():637065. PubMed ID: 25136676
[TBL] [Abstract][Full Text] [Related]
8. Mechanistic insights into CKD-MBD-related vascular calcification and its clinical implications.
Kaur R; Singh R
Life Sci; 2022 Dec; 311(Pt B):121148. PubMed ID: 36336124
[TBL] [Abstract][Full Text] [Related]
9. Vascular calcification in CKD: New insights into its mechanisms.
Ding N; Lv Y; Su H; Wang Z; Kong X; Zhen J; Lv Z; Wang R
J Cell Physiol; 2023 Jun; 238(6):1160-1182. PubMed ID: 37269534
[TBL] [Abstract][Full Text] [Related]
10. Vascular Calcification: An Important Understanding in Nephrology.
Zununi Vahed S; Mostafavi S; Hosseiniyan Khatibi SM; Shoja MM; Ardalan M
Vasc Health Risk Manag; 2020; 16():167-180. PubMed ID: 32494148
[TBL] [Abstract][Full Text] [Related]
11. Oxidative stress contributes to vascular calcification in patients with chronic kidney disease.
Huang M; Zheng L; Xu H; Tang D; Lin L; Zhang J; Li C; Wang W; Yuan Q; Tao L; Ye Z
J Mol Cell Cardiol; 2020 Jan; 138():256-268. PubMed ID: 31866376
[TBL] [Abstract][Full Text] [Related]
12. Hyperphosphatemia-induced degradation of transcription factor EB exacerbates vascular calcification.
Ishiwata R; Morimoto Y
Biochim Biophys Acta Mol Basis Dis; 2022 Mar; 1868(3):166323. PubMed ID: 34921974
[TBL] [Abstract][Full Text] [Related]
13. Therapy for the altered mineral metabolism of chronic kidney disease: implications for vascular calcification.
Saab G; Whaley-Connell AT; Khanna R; Sowers JR
Ther Adv Cardiovasc Dis; 2007 Dec; 1(2):107-12. PubMed ID: 19124399
[TBL] [Abstract][Full Text] [Related]
14. The WNT/β-catenin system in chronic kidney disease-mineral bone disorder syndrome.
Zhang L; Adu IK; Zhang H; Wang J
Int Urol Nephrol; 2023 Oct; 55(10):2527-2538. PubMed ID: 36964322
[TBL] [Abstract][Full Text] [Related]
15. Vascular calcification in skin and subcutaneous tissue in patients with chronic and end-stage kidney disease.
Ruderman I; Hewitson TD; Smith ER; Holt SG; Wigg B; Toussaint ND
BMC Nephrol; 2020 Jul; 21(1):279. PubMed ID: 32677907
[TBL] [Abstract][Full Text] [Related]
16. Phosphate and Coronary Artery Disease in Patients with Chronic Kidney Disease.
Ogata H; Sugawara H; Yamamoto M; Ito H
J Atheroscler Thromb; 2024 Jan; 31(1):1-14. PubMed ID: 37766573
[TBL] [Abstract][Full Text] [Related]
17. Development of a novel chronic kidney disease mouse model to evaluate the progression of hyperphosphatemia and associated mineral bone disease.
Tani T; Orimo H; Shimizu A; Tsuruoka S
Sci Rep; 2017 May; 7(1):2233. PubMed ID: 28533541
[TBL] [Abstract][Full Text] [Related]
18. Pathophysiology of Vascular Calcification.
Chen NX; Moe SM
Curr Osteoporos Rep; 2015 Dec; 13(6):372-80. PubMed ID: 26409849
[TBL] [Abstract][Full Text] [Related]
19. Vascular toxicity of phosphate in chronic kidney disease: beyond vascular calcification .
Gross P; Six I; Kamel S; Massy ZA
Circ J; 2014; 78(10):2339-46. PubMed ID: 25077548
[TBL] [Abstract][Full Text] [Related]
20. Osteo-renal regulation of systemic phosphate metabolism.
Razzaque MS
IUBMB Life; 2011 Apr; 63(4):240-7. PubMed ID: 21438115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
